Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism oflevodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.
CAT No: 10-101-135
CAS No:28860-95-9 (net), 38821-49-7 (monohydrate)
Synonyms/Alias:lodosyn; CARBIDOPA 1-HYDRATE; CARBIDOPA MONOHYDRATE; (S)-3-(3,4-Dihydroxyphenyl)-2- hydrazino-2-methylpropanoic acid · H2O; (S)-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid monohydrate; (-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate; α-Methyldopahydrazine monohydrate; MK485, MK 485, MK-485, Carbidopa, Lodosyn
Chemical Name:(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
Carbidopa is a hydrazine derivative commonly recognized for its pivotal role in biochemical research and pharmaceutical development, particularly as a decarboxylase inhibitor. Characterized by its ability to cross the blood-brain barrier minimally, Carbidopa is often utilized in combination with other compounds to modulate enzymatic activity and neurotransmitter synthesis. Its chemical structure allows it to interact selectively with aromatic L-amino acid decarboxylase, making it a valuable tool for researchers investigating metabolic pathways and enzyme inhibition. With a stable profile under standard laboratory conditions, Carbidopa enables precise experimental control, supporting advanced studies in neurochemistry and metabolic regulation.
Neurotransmitter Biosynthesis Studies: Carbidopa is extensively applied in the study of neurotransmitter biosynthesis, particularly in the modulation of dopamine production. By inhibiting peripheral aromatic L-amino acid decarboxylase, it prevents the premature conversion of L-DOPA to dopamine outside the central nervous system, thus facilitating accurate assessment of central dopamine synthesis. Researchers employ this compound to delineate the pathways involved in neurotransmitter metabolism, providing insights into the regulation of dopaminergic signaling and its implications in neurological disorders.
Enzyme Inhibition Mechanisms: The compound serves as a model inhibitor in studies aimed at elucidating the mechanisms of enzyme inhibition. Its selective action on aromatic L-amino acid decarboxylase enables detailed investigation into competitive and non-competitive inhibition processes. Scientists utilize Carbidopa to dissect the kinetics of enzyme-substrate interactions, advancing the understanding of how specific inhibitors can modulate enzymatic activity. This knowledge is instrumental in the rational design of novel inhibitors for research and therapeutic purposes.
Pharmacokinetic Research: In pharmacokinetic studies, Carbidopa is used to explore the absorption, distribution, metabolism, and excretion of co-administered agents, particularly those targeting the central nervous system. By limiting peripheral metabolism, it allows researchers to assess the bioavailability and central effects of various compounds without confounding peripheral conversion. This application is crucial for optimizing dosing regimens and understanding the systemic handling of neuroactive agents in experimental models.
Metabolic Pathway Elucidation: Carbidopa contributes significantly to the elucidation of metabolic pathways involving aromatic amino acids. Its inhibitory effect on decarboxylase activity permits the accumulation and subsequent measurement of metabolic intermediates, enabling comprehensive mapping of biochemical routes. Researchers leverage this property to investigate disorders of amino acid metabolism, identify novel metabolites, and characterize the flux of substrates through interconnected pathways.
Preclinical Model Development: In the development of preclinical models, Carbidopa is employed to simulate and manipulate neurotransmitter dynamics in vivo. By controlling peripheral enzyme activity, it provides a means to study the central effects of exogenous precursors and to model disease states associated with neurotransmitter imbalance. This application supports the validation of new hypotheses in neurobiology and the evaluation of potential research compounds targeting the central nervous system.
Carbidopa stands as an indispensable reagent in contemporary biochemical and pharmacological research, offering nuanced control over enzyme activity and metabolic processes. Its applications span from fundamental studies of neurotransmitter biosynthesis to advanced pharmacokinetic profiling and metabolic pathway analysis. By enabling precise manipulation of enzymatic reactions and neurotransmitter levels, it empowers researchers to unravel the complexities of neurochemical regulation and metabolic networks. As the scientific community continues to probe the intricacies of brain function and systemic metabolism, Carbidopa remains a cornerstone compound, facilitating discoveries that drive innovation in neuroscience, enzymology, and metabolic research.
A double-blind study comparing the effects of carbidopa and levodopa combined in a single tablet with levodopa alone was undertaken in 50 patients with Parkinson's disease. After 6 months, there was a statistically significant improvement over baseline in total score, rigidity, and tremor only in the patients randomized to carbidopa/levodopa. In addition, 40 percent of the patients treated with carbidopa/levodopa showed obvious clinical improvement (a greater than 50 percent reduction in their total score) over treatment with levodopa alone. However, after 2 years, only 20 percent continued to show this improvement. Nausea, vomiting, and anorexia developed in 56 percent of patients on levodopa but in only 27 percent of patients on carbidopa/levodopa. However, abnormal involuntary movements, observed in 48 percent of patients on levodopa, were present in 77 percent of patients on carbidopa/levodopa. Despite the increase in abnormal involuntary movements, carbidopa/levodopa is more effective than levodopa.
Lieberman, A., Goodgold, A., Jonas, S., & Leibowitz, M. (1975). Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease. Neurology, 25(10), 911-911.
Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is associated with the development of motor complications. Mounting evidence indicates the short half-life of levodopa and resultant pulsatile stimulation of striatal dopamine receptors leads to wearing off, motor fluctuations and dyskinesias. Longer acting dopaminergic agents, such as dopamine agonists, are less likely to cause motor fluctuations and dyskinesias but are not as efficacious for control of motor symptoms. Therefore, there is interest in exploring ways to deliver levodopa in a more continuous fashion, in an effort to maintain benefit through the day and reduce the development of motor fluctuations and dyskinesias. A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central bioavailability. When levodopa is administered with a DDCI, its main route of peripheral metabolism is via catechol-O-methyl transferase (COMT).
Seeberger, L. C., & Hauser, R. A. (2009). Levodopa/carbidopa/entacapone in Parkinson’s disease. Expert review of neurotherapeutics, 9(7), 929-940.
2. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
4. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More